Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer

Su, Y; Liu, Y; Behrens, CR; Bidlingmaier, S; Lee, NK; Aggarwal, R; Sherbenou, DW; Burlingame, AL; Hann, BC; Simko, JP; Premasekharan, G; Paris, PL; Shuman, MA; Seo, Y; Small, EJ; Liu, B

Liu, B (reprint author), UCSF, Dept Anesthesia, 1001 Potrero Ave,1305, San Francisco, CA 94143 USA.

JCI INSIGHT, 2018; 3 (17):

Abstract

Although initially responsive to androgen signaling inhibitors (ASIs), metastatic castration-resistant prostate cancer (mCRPC) inevitably develops and......

Full Text Link